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ABSTRACT:
Formation of an acyl-CoA thioester has been proposed, but not
directly demonstrated, to be a key step in mediating both lacton-
ization and atypical -oxidation of 3-hydroxy-3-methylglutaryl-CoA
reductase inhibitors. Here, we describe studies to characterize
formation of acyl-CoA thioesters in vitro in mouse liver prepara-
tions using the hydroxy acid form of simvastatin (SVA) as a model
substrate. With an optimized chromatography method, three new
products were detected in addition to the dehydration product (P1)
and the lactone form of simvastatin, which have been character-
ized previously (Prueksaritanont et al., 2001). Based on high-pres-
sure liquid chromatography analysis, UV spectroscopy, mass
spectrometry, and NMR spectral characterization, two metabolites
were identified as acyl-CoA thioester conjugates of SVA and P1,
respectively, whereas the third metabolite (M1) was confirmed to
be the L--hydroxy isomer of simvastatin. M1 was probably formed
by stereospecific hydration, a previously reported reaction, and
subsequent lactonization of P1-S-acyl CoA. Among all the mouse
liver subcellular fractions, microsomes exhibited the highest ca-
pacity to catalyze the CoASH-dependent metabolism of SVA,
whereas such activity was totally absent in cytosol. Together,
these results provide direct experimental evidence that SVA (and
conceivably other statins as well) is able to form an acyl-CoA
thioester, possibly by microsomal long-chain acyl-CoA syntheta-
se(s), leading to formation of two parallel metabolic pathways, one
resulting in the two diastereomers of statin lactones (simvastatin
and M1) and the other to the -oxidation pathway of statin hydroxy
acids.
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase inhibitors (statins) are a well established class of drugs used
widely in the treatment of hypercholesterolemia due to their tol-
erability, proven efficacy, and convenient administration. Except
for simvastatin and lovastatin, all current statins are administered
as the pharmacologically active hydroxy acid form. Simvastatin
and lovastatin are administered as inactive lactones, which upon
hydrolysis to their respective hydroxy acids (SVA and LVA), serve
as potent competitive inhibitors of HMG-CoA reductase, the rate-
limiting enzyme in de novo cholesterol biosynthesis (Duggan and
Vickers, 1990).
All statins, with the exception of pravastatin (Hatanaka, 2000)
and the recently approved rosuvastatin (Martin et al., 2000), are
extensively metabolized before elimination (Reinoso et al., 2002).
The common metabolic pathways of these statins include cyto-
chrome P450-mediated oxidative metabolism (Igel et al., 2001),
acyl glucuronidation (Prueksaritanont et al., 2002a,b), and -oxi-
dation (Reinoso et al., 2002). Like the acyl glucuronidation, the
-oxidation occurs at the dihydroxy heptanoic or heptenoic acid
side chain, a structural feature common to all statin hydroxy acids
(SVA structure, as an example, is shown in Fig. 1). The pentanoic
and/or propanoic acid products corresponding to one and/or two
cycles of -oxidation, respectively, have been reported to occur
exclusively in rodents following lovastatin, simvastatin, and cer-
ivastatin administration and predominantly so for other statins
(Vickers et al., 1990; Halpin et al., 1993; Boberg et al., 1998;
Reinoso et al., 2002). Acyl-CoA thioesters of these statin hydroxy
acids have been proposed to be the key intermediates for the
formation of these -oxidation metabolites (Fig. 1). Evidence that
supports this proposal, however, is very limited. Recent studies in
our laboratory have provided some evidence that formation of the
-oxidation products of SVA in vitro in mouse liver preparations
was mediated by CoASH-dependent enzyme(s) (Prueksaritanont et
al., 2001). Unfortunately, acyl-CoA thioesters of SVA and its
-oxidation intermediates were not detected in the study. There-
fore, the present studies were undertaken, using an in vitro ap-
proach and SVA as a model substrate, to characterize the formation
of these acyl-CoA thioester intermediates in mouse liver subcel-
lular fractions and to provide support for the mechanism of the
-oxidation of statins proposed by Halpin et al. (1993). Here, we
demonstrate that acyl-CoA conjugates of SVA and its dehydration
product (P1) were formed in vitro in mouse liver preparations and
were primarily catalyzed by microsomal enzymes. Additionally,
the findings of CoASH-dependent formation of simvastatin and its
diastereomer M1 substantiate the mechanism proposed previously
for the in vivo lactonization of statin hydroxy acids (Duggan and
Vickers, 1990).
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Materials and Methods
Materials. Simvastatin and SVA were synthesized at Merck Research
Laboratories (Rahway, NJ). Triton X-100, CoASH, ATP, and palmitoyl-S-acyl
coenzyme A (PA-CoA) were obtained from Sigma-Aldrich (St. Louis, MO).
[1-14C]Palmitic acid and [1-14C]octanoic acid were obtained from GE Health-
care (Little Chalfont, Buckinghamshire, UK) and American Radiolabeled
Chemicals, Inc. (St. Louis, MO), respectively. All other agents were of
analytical or HPLC grade.
Animals. All animal studies were approved by the Merck Research Labo-
ratories Institutional Animal Care and Use Committee. Ten male CD-1 mice
(25–40 g) were obtained from Charles River Laboratories (Wilmington, MA).
Following cervical dislocation, livers were quickly removed, weighed, and
washed with 1.15% potassium chloride. The livers were homogenized in 4
volumes of ice-cold medium containing 250 mM sucrose, 10 mM HEPES, and
1 mM EDTA. The liver subcellular fractions were prepared by differential
centrifugation as described previously with minor modifications (Bjorge and
Baillie, 1991). In brief, liver homogenates were centrifuged first at 600g for 10
min to remove nuclei and cell debris. The supernatant (S0.6) was centrifuged
at 3300g for a further 10 min to sediment the heavy mitochondria (MT-H). The
resulting supernatant (S3) was then centrifuged at 27,000g for 10 min to obtain
the light mitochondria fraction (MT-L). The corresponding supernatant (S27)
was finally centrifuged at 100,000g for 1 h to prepare the liver microsomes.
The residue supernatant was taken as the cytosolic fraction. The purity of each
of the fractions was assessed by the activity of their respective marker en-
zymes: catalase for peroxisomes (Baudhuin et al., 1964), cytochrome c oxidase
for mitochondria (Sellinger et al., 1960), lactate dehydrogenase for cytosol
(Volkl and Fahimi, 1985), and NADPH-cytochrome c reductase for micro-
somes (Beaufay et al., 1974).
In Vitro Metabolism. Incubations of SVA (100 M) with mouse liver
subcellular fractions (1.5 mg/ml) were carried out in triplicate in 150 mM
Tris-HCl buffer (pH 8.0) containing 0.05% Triton X-100, 1.2 mM CoASH, 10
mM MgCl2, and 5 mM ATP in a final volume of 0.2 ml. After a 3-min
preincubation, reactions were initiated by the addition of ATP and incubated
for up to 60 min at 37°C. The reactions were terminated at appropriate time
intervals by the addition of 120 l of ice-cold acetonitrile. After centrifugation
at 10,000g for 10 min, the supernatant was analyzed immediately by HPLC or
LC-MS with an autosampler set at 5°C to minimize any degradation that might
have occurred during the sample handling and analysis. Preliminary stability
studies showed that SVA-S-acyl coenzyme A (SVA-CoA) and its subsequent
metabolites were stable under the conditions described above. Control exper-
iments included incubation mixtures with one or more components missing.
Incubations with [1-14C]palmitic acid (50 M) and [1-14C]octanoic acid (50
M) were performed under the same conditions as described above for SVA,
except that the mixtures contained 0.025 mg/ml mouse liver subcellular
fractions for palmitic acid and 0.125 mg/ml for octanoic acid, and were
incubated for 5 min. Under such incubation conditions, the formation of
PA-CoA and octanoyl-S-acyl coenzyme A (OA-CoA) was linear with incuba-
tion time and protein concentration.
For isolation and purification of metabolites of SVA, large-scale incuba-
tions of SVA (500 M) were carried out with mouse liver microsomes (1.5
mg/ml), CoASH (1.2 mM), and ATP (5 mM) for 40 min in a final volume of
12 ml for the isolation of SVA-CoA and P1-S-acyl coenzyme A (P1-CoA) or
FIG. 1. Proposed pathway for CoASH-dependent metabolism of SVA.
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for 3 h in a final volume of 60 ml for M1. The incubation mixtures were
terminated with half a volume of acetonitrile and loaded onto C18 solid-phase
extraction cartridges (Oasis HLB SPE cartridge; Waters Corporation, Milford,
MA), which were pre-equilibrated with water and acetonitrile. The acyl-CoA
thioesters containing fractions were eluted with 70% acetonitrile, whereas
M1-containing fraction was eluted with 90% acetonitrile. The resulting solid-
phase eluates were evaporated to dryness, reconstituted in 5 to 10 ml of the
mobile phase (20% acetonitrile in 10 mM ammonium acetate buffer, pH  7),
and isolated by preparative HPLC as described below. The purified metabolites
were characterized by NMR spectroscopy.
Analytical Methods. SVA and its metabolites were analyzed using pub-
lished HPLC methods with some modifications (Prueksaritanont et al., 1999).
In brief, samples held in an autosampler (set at 5°C) were chromatographed on
a C18 Zorbax column (150  4.6 mm, 5 m; Agilent Technologies, Palo Alto,
CA) with a linear gradient of acetonitrile and 10 mM ammonium acetate (pH
7). The eluates were monitored by UV absorption at 240 and 260 nm. Due to
the unavailability of authentic standards for SVA-CoA and P1-CoA, the
concentrations of these metabolites in the in vitro incubation mixtures were
estimated using standard curves for PA-CoA at 260 nm, assuming similar
extinction coefficients between SVA-CoA (or P1-CoA) and PA-CoA. Evi-
dence that supports the assumption includes the observations that SVA, P1,
and palmitic acid all had minimal UV absorption at 260 nm, whereas the
corresponding acyl-CoA thioesters and free CoASH exhibited maximal UV
absorption at 260 nm. In addition, PA-CoA was selected because of its similar
HPLC retention time to SVA-CoA and P1-CoA under the HPLC conditions
described above. Quantification of P1 and M1 in the in vitro incubations was
accomplished using standard curves for SVA and simvastatin, respectively,
assuming identical extraction recoveries and extinction coefficients at their
maximal UV absorption at 240 nm.
Metabolite isolation was accomplished by semipreparative HPLC (Waters)
coupled with a fraction collector (Foxy 200; ISCO, Inc., Lincoln, NE). The
reconstituted reaction mixtures were separated on a Luna C18(2) column
(250  10 mm, 5 m; Phenomenex, Torrance, CA) with a 40-min gradient
from 80% A (10% methanol in 10 mM ammonium acetate, pH 7) to 70% B
(90% acetonitrile in water). Fractions corresponding to the peaks for the SVA
metabolites were collected according to UV absorbance at 260 nm for SVA-
CoA and P1-CoA and 240 nm for M1.
Analysis of PA-CoA and OA-CoA in mouse liver preparations was per-
formed on a Hypersil BDS C8 column (150  4.6 mm, 5 m; Thermo Electron
Corporation, Waltham, MA) with a linear gradient of acetonitrile and 25 mM
ammonium acetate (pH 7). The acyl-CoA thioesters were monitored by UV
absorption at 260 nm and by an on-line IN/US -RAM radioactivity detector
(IN/US Systems, Tampa, FL).
LC-MS analysis was conducted on a Finnigan MAT LCQ ion trap mass
spectrometer (Thermo Electron Corporation), interfaced with a PerkinElmer
HPLC system (PerkinElmer Life and Analytical Sciences, Boston, MA)
equipped with two Series 200 micropumps and an autosampler set at 5°C.
LC-MS and LC-MS/MS experiments were carried out using electrospray
ionization in the negative ion mode (for SVA, P1, SVA-CoA, and P1-CoA) or
positive ion mode (for lactones simvastatin and M1). The electrospray ioniza-
tion voltage was set at 3.5 kV, with the heated capillary temperature held at
175°C. A C18 Zorbax column (150  4.6 mm, 5 m; Agilent Technologies)
was used for chromatographic separation and was eluted at 1.0 ml/min with a
gradient of 10 mM ammonium acetate (pH 7) in water with 10% methanol (A)
and 90% acetonitrile in water (B). The initial mobile phase consisted of 15%
B, which remained unchanged for 5 min and increased linearly to 70% B over
22 min, then to 90% over 1 min, and held for 5 min. One-fifth of the flow was
directed into the mass spectrometer, and the remainder was used for UV
detection at 240 nm.
Accurate mass measurements were conducted on a Micromass Q-TOF
(quadrupole time-of-flight) II mass spectrometer (Waters) operated in the
positive electrospray ionization mode with a LockSpray reference sprayer. The
source and desolvation gas temperatures were set at 80°C and 180°C, respec-
tively. The capillary voltage, cone voltage, and collision energies were 2.5 kV,
25 V, and 15 V, respectively. The instrument was calibrated by infusing
aqueous 0.01% phosphoric acid solution through a syringe pump at 5 l/min
prior to the experiment. The same calibration solution was used as the lock
mass in the sample analysis. The chromatographic conditions used in Q-TOF
experiments were the same as described above.
NMR studies were performed at 10°C for CoASH and acyl-CoA thioesters
FIG. 2. Representative HPLC-UV profiles of SVA metabolites in incubations with mouse liver S0.6 (A), microsomes (B), and cytosol (C). Incubations were carried out
at 37°C for 20 min using mouse liver subcellular fractions (1.5 mg/ml) and SVA (100 M) with 1.2 mM CoASH and 5 mM ATP.
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and at 25°C for the SVA, simvastatin, and M1 samples. All NMR data were
collected either on a 500- or 600-MHz spectrometer (Varian Inc., Palo Alto,
CA), both equipped with a 5-mm HCN Cold Probe (Varian Inc.). The HPLC
isolates or the authentic standard(s) were dissolved in 160 l of CD3OD
[except for CoASH, where 10% D2O (v/v) was added to promote solubility]
and transferred to 3-mm tubes. 1D 1H, 2D 1H-1H correlation, 2D 1H-13C
one-bond, and multiple-bond correlation data sets were acquired for all sam-
ples and used to elucidate the structures.
Results
Metabolite Identification. Figure 2, A and B, illustrates typical
HPLC chromatograms derived from incubations of mouse liver sub-
cellular fractions (S0.6 and microsomes) with SVA in the presence of
CoASH and ATP. Five metabolites (designated as SVA-CoA, P1-
CoA, P1, M1, and simvastatin) were detected by UV absorption at 240
nm. P1, M1, and simvastatin exhibited UV absorption spectra similar
to SVA, whereas SVA-CoA and P1-CoA had UV absorption peak at
260 nm (characteristics for CoASH) in addition to the well charac-
terized UV peak for SVA at 240 nm. P1, which gave a deprotonated
ion [M  H] at m/z 417, has been identified previously by NMR as
the dehydration product of SVA (Prueksaritanont et al., 2001). The
product, which eluted last in the chromatogram, was identified as the
simvastatin lactone based on the identical HPLC retention time and
UV spectrum compared with the authentic standard. Except for a
small amount of simvastatin (0.1% of initial concentration), the
remaining four SVA metabolites were not detectable in incubations
with mouse liver cytosol (Fig. 2C) and control incubations that lacked
liver protein, ATP, or CoASH. The results suggested that formation of
SVA-CoA, P1-CoA, P1, and M1 was mediated by CoASH- and
ATP-dependent enzyme(s), whereas simvastatin was formed by both
enzymatic (by CoASH- and ATP-dependent enzymes) and chemical
(to a lesser extent) processes under the conditions described under
Materials and Methods.
The mass spectrum of SVA-CoA showed a prominent [M  H]
ion at m/z 1184.4, 749 (CoASH  H2O) mass units higher than the
[M  H] ion of SVA. MS/MS fragmentation of m/z 1184.4
showed peaks indicative of a CoASH moiety attached to SVA,
including ions at m/z 766.2 ([CoAS]), m/z 426.1 ([adenosine
diphosphate]), m/z 408.2 ([adenosine diphosphate  H2O]
), m/z
1104.5 ([SVA-CoA  H2PO3]
), m/z 1086.5 ([SVA-CoA  di-
methyl-oxobutyl]), m/z 1049.4 ([SVA-CoA  adenine  2H]),
and m/z 837.4 ([SVA-CoA  adenosine monophosphate  2H])
(Fig. 3A). NMR studies with the isolated metabolite confirmed it
to be an acyl-CoA conjugate of SVA with a thioester bond between
SVA and CoASH. The combined NMR data clearly showed that
the SVA and CoASH moieties were fully intact in the adduct
spectrum. The methylene group, labeled 3, in the SVA portion of
the adduct appeared at H 2.71, 2.77 ppm/C 50.8 ppm (Table 1).
The -methylene group, labeled a, of the mercaptoethylamine
subunit in CoASH appeared at H 3.00 ppm/C 27.9 ppm (Table 1).
A 2 D 1H-13C multibond correlation (a select expansion of the
FIG. 3. MS/MS spectra of SVA-CoA (A) and P1-CoA (B) and tentative assignments of the fragment ions.
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spectrum displayed in Fig. 4) was observed from both methylene
protons 3 and a to the carbonyl carbon 2 (at 197.9 ppm) in the
SVA heptanoic acid side chain. Therefore, the combined NMR
data showed that the sulfur of the CoASH was conjugated to the
acyl carbon 2 of the heptanoic acid side chain in SVA.
The identification of P1-CoA was based on UV, MS, MS/MS, and
NMR spectra. P1-CoA gave rise to a deprotonated ion [M  H] at
m/z 1166.4, 749 (CoASH  H2O) mass units higher than the [M 
H] ion of P1 and 18 mass units less than that of SVA-CoA thioester
(m/z 1184.4), suggesting possible dehydration of SVA-CoA. Consis-
tently, the MS/MS spectrum of P1-CoA displayed a family of product
ions, including ions m/z 1086.5 ([P1-CoA  H2PO3]
), m/z 1068.5
([P1-CoA  dimethyl-oxobutyl]), m/z 1031.4 ([P1-CoA  ade-
nine  2H]), and m/z 819.4 ([P1-CoA  adenosine monophos-
phate  2H]) (Fig. 3B), which were all 18 mass units less than the
corresponding fragment ions of SVA-CoA. In addition, the product
ions at m/z 426.1 and 408.2, corresponding to adenosine diphosphate
and its dehydration ions, remained the same as those of SVA-CoA,
FIG. 4. Select expansion of a 2D 1H-13C multibond correlation NMR spectrum of SVA-CoA. Labels are shown in Fig. 1.
TABLE 1
1H and 13C chemical shifts of SVA, simvastatin, and CoASH-dependent SVA metabolites
All chemical shifts are referenced to CD2HOD peak set at H 3.30/C 47.9 ppm. The decalin ring and the dimethyl butanoic acid moieties are unchanged in all structures, and their chemical
shifts in all structures were practically identical to previously published data on SVA (Prueksaritanont et al., 2001).
Labela
SVA and CoASHb SVA-CoA P1-CoA Simvastatin M1
1H 13C 1H 13C 1H 13C 1H 13C 1H 13C
2 178.5 197.9 190.0 172.0 172.3
3 2.28, 2.39 43.9 2.71, 2.77 50.8 6.22 129.9 2.52, 2.71 37.7 2.35, 2.85 38.7
4 4.08 67.8 4.21 66.8 6.90 142.6 4.24 61.9 4.19 62.8
5 1.55 43.8 1.60 43.4 2.35 40.0 1.74, 1.91 35.2 1.49, 2.24 37.5
6 3.69 70.3 3.63 69.9 3.57 71.0 4.61 76.7 4.19 77.8
7 1.27, 1.54 34.4 1.17, 1.54 32.9 1.17, 1.55 34.1 1.35, 1.82 32.7 1.36, 1.85 32.6
8 1.40 24.5 1.34 24.4 1.37 24.7 1.39, 1.49 23.9 1.41, 1.49 24.6
a 2.58 23.1 3.00 27.9 3.04 27.6
b 3.31 42.5 3.31 38.6 3.32 38.8
c 172.8 172.7 172.7
d 2.45 35.3 2.41 35.2 2.43 35.3
e 3.46 35.1 3.45 35.1 3.46 35.1
f 174.3 174.4 174.4
g 4.05 73.9 4.06 73.5 4.08 73.5
h 38.8 38.7 38.7
h-Me 0.82, 1.02 18.3, 20.8 0.83, 1.05 18.1, 21.0 0.82, 1.05 18.1, 20.9
i 3.59, 3.96 71.8 3.56, 3.98 71.8 3.57, 3.99 71.7
R1 6.13 87.4 6.12 87.1 6.14 87.1
R2, R4 4.76, 4.92 74.1, 74.6 4.79, 4.86 74.1, 74.4 4.79, 4.92 74.1, 74.5
R3 4.52 83.3 4.50 83.4 4.50 83.4
R5 4.28 64.9 4.24 65.1 4.23, 4.30 64.9
A2 8.22 150.3 8.20 152.4 8.20 152.4
A6 8.62 140.6 8.57 139.6 8.59 139.7
a Labels are shown in Fig. 1.
b Chemical shifts of a to i, R1 to R5, and A2 and A6 in this column correspond to the CoASH standard in 90% CD3OD/10% D2O.
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indicating that the adenosine phosphate moiety was intact (Fig. 3B).
NMR data supported that P1-CoA was an acyl-CoA conjugate of P1
with a thioester bond between P1 and CoASH. The combined NMR
data conclusively indicated that the P1 and CoASH moieties were
intact. The proton shifts of P1 moiety were similar to the previously
published data on P1, the dehydration metabolite of SVA (Prueksari-
tanont et al., 2001). Alkene carbons 3 and 4 in the P1 moiety appeared
at H 6.22 ppm/C 129.9 ppm and H 6.90 ppm/C 142.6 ppm,
respectively (Table 1). The -methylene group, labeled a, of the
mercaptoethylamine subunit in CoASH appeared at H 3.04 ppm/C
27.6 ppm (Table 1). A common 2 D 1H-13C multibond correlation was
observed from the protons 3 and 4 of P1 moiety and methylene
protons a to the carbonyl carbon 2 at 190.0 ppm (not shown).
Therefore, NMR data conclusively indicated the site of CoASH sulfur
conjugation to be at the acyl carbon 2 of P1 moiety.
M1 was identified as L--hydroxy isomer of simvastatin based on
UV, accurate MS, MS/MS, and NMR spectra. Accurate mass mea-
surements by a Q-TOF instrument revealed that the [M  H] of
simvastatin standard and M1 were at m/z 419.2788 and 419.2804,
respectively, which were all within 2.2 ppm of the calculated mass of
[simvastatin  H]. In the high-resolution MS/MS experiment, the
residual parent ion signal was used as the internal lock mass. MS/MS
spectra of simvastatin and M1 exhibited almost identical fragmenta-
tion patterns except for the relative intensities of fragment ions (not
shown). The observed and calculated m/z values of the most abundant
fragment ions of simvastatin and M1 are shown in Table 2, which
confirmed the fragmentation pathway proposed in Fig. 5. Therefore,
high-resolution MS data strongly suggested that simvastatin and M1
were positional isomers. The NMR data on M1 was consistent with a
chiral center inversion at carbon 4, which is part of the six-member
lactone ring. 1H chemical shifts of simvastatin standard and M1 are
shown in Table 1. Comparing the two 1D 1H NMR spectra, the
FIG. 5. Proposed fragmentation pathway for simvastatin and M1. The accurate mass measurement data are summarized in Table 2.
TABLE 2
Observed and calculated m/z values of the most abundant fragment ions in the MS/MS spectra of simvastatin standard and M1
The calculated values and formulas are based on the fragmentation assigned in Fig. 5. The MS/MS spectra were obtained using a Micromass Q-TOF mass spectrometer (see text for details).




 173.1328 173.1325 0.3 1.7
C15H19
 199.1486 199.1481 0.5 2.5
C17H21
 225.1638 225.1638 0.0 0.0
C17H23O
 243.1744 243.1743 0.1 0.4
C19H23O
 267.1762 267.1743 1.9 7.1
C19H25O2
 285.1856 285.1849 0.7 2.5
C19H27O3
 303.1964 303.1955 0.9 3.0
M1
C13H17
 173.1326 173.1325 0.1 0.6
C15H19
 199.1490 199.1481 0.9 4.5
C17H21
 225.1655 225.1638 1.7 7.6
C17H23O
 243.1744 243.1743 0.1 0.4
C19H23O
 267.1742 267.1743 0.1 0.4
C19H25O2
 285.1855 285.1849 0.6 2.1
C19H27O3
 303.1945 303.1955 1.0 3.3
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spectral changes were observed for protons in the six-member lactone
ring. The CHOH methine protons, labeled 4 and 6, appeared at 4.24
and 4.61 ppm, respectively, in simvastatin (Table 1). In contrast, H4
and H6 were overlapped and appeared at 4.19 ppm in the M1 spec-
trum (Table 1). The methine carbons at 4 and 6 were resolved in the
2D 1H-13C one-bond correlation spectrum of M1 at 62.8 and 77.8
ppm, respectively (not shown).
Metabolism of SVA in Mouse Liver Subcellular Fractions.
Time-dependent studies with mouse liver S0.6 showed that formation
of SVA-CoA and P1-CoA increased rapidly during the first 10 to
20-min incubations and then decreased steadily thereafter, whereas
formation of P1, M1, and simvastatin seemed to increase gradually
with incubation time (Fig. 6A). In addition to mouse liver S0.6,
CoASH-dependent metabolism of SVA was also observed in incuba-
tions with other mouse liver subcellular fractions, including mitochon-
dria (MT-H and MT-L) and microsomes (Fig. 7C). The identities and
purities of these subcellular fractions were confirmed by marker
enzyme analysis (Table 3). Among all the mouse subcellular fractions,
microsomes exhibited the highest capability to catalyze CoASH-
dependent metabolism of SVA on a per-milligram-of-protein basis,
FIG. 6. Time-dependent formation of SVA metabolites following incubations with mouse liver S0.6 (A) and microsomes (B). Incubations were carried out in triplicate at
37°C using mouse liver subcellular fractions (1.5 mg/ml) and SVA (100 M) with 1.2 mM CoASH and 5 mM ATP. Values represent means  S.D. from triplicate
incubations.
FIG. 7. Mouse liver subcellular distribution of enzyme activity responsible for the formation of PA-CoA (A), OA-CoA (B), and CoA-dependent metabolism of SVA (C).
Incubations of SVA (100 M) with mouse liver subcellular fractions (1.5 mg/ml) were carried out in triplicate at 37°C for 20 min in 150 mM Tris-HCl buffer (pH 8.0)
containing 1.2 mM CoASH and 5 mM ATP. Incubations with [1-14C]palmitic acid (50 M) and [1-14C]octanoic acid (50 M) were performed under the same conditions
as described above for SVA, except that the mixtures contained 0.025 mg/ml of mouse liver subcellular fractions for palmitic acid and 0.125 mg/ml for octanoic acid and
were incubated for 5 min. Values represent means  S.D. from triplicate incubations.
TABLE 3
Marker enzyme activities in mouse liver subcellular fractions
Units for catalase and lactate dehydrogenase are micromoles per minute per milligram of protein; units for cytochrome c oxidase and cytochrome c reductase are nanomoles per minute per
milligram of protein. Values represent means  S.D. from triplicate incubations.
Marker Enzymes SpecificActivity of S0.6
Specific Activity Relative to S0.6
S3 MT-H S27 MT-L Cytosol Microsomes
Catalase 167  13 0.83  0.01 1.26  0.08 0.52  0.04 2.79  0.10 0.68  0.04 0.41  0.01
Cytochrome c oxidase 217  3 0.72  0.04 3.21  0.23 0.29  0.07 2.89  0.52 0.02  0.03 0.93  0.16
Lactate dehydrogenase 11.1  1.0 0.99  0.11 0.18  0.11 1.08  0.08 0.06  0.003 1.63  0.18 0.08  0.004
Cytochrome c reductase 9.7  0.6 0.94  0.10 0.03  0.01 1.26  0.05 0.10  0.02 0.24  0.01 3.56  0.19
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whereas cytosol was totally incapable of catalyzing the reaction (Figs.
2C and 7C). As illustrated in Figs. 2B and 6B, incubations of SVA
with mouse liver microsomes produced significantly higher levels of
SVA-CoA and P1-CoA thioesters (approximately 5- to 7-fold higher
after 20-min incubations) than that of mouse liver S0.6. Consistently,
the lactonization products simvastatin and M1 were also found to be
approximately 5- to 7-fold higher after 1-h incubations with mouse
liver microsomes than the corresponding incubations with S0.6. These
results provided additional support for the acyl-CoA thioester-depen-
dent mechanism proposed previously for the lactonization of the
hydroxy acid forms of statins observed in vivo (Duggan and Vickers,
1990). Interestingly, P1 levels in microsomes were not significantly
more than in S0.6.
Due to the apparent subsequent metabolism of SVA-CoA in mouse
liver preparations, the sum of the five metabolites (SVA-CoA, P1-
CoA, P1, M1, and simvastatin) was used to compare the rates of
CoASH-dependent metabolism of SVA in mouse liver subcellular
fractions. Preliminary studies showed that CoASH-dependent metab-
olism of SVA was linear with time up to 30 min and with mouse liver
S0.6 up to 3 mg/ml. As shown in Fig. 7C and Table 3, the rate of
CoASH-dependent metabolism of SVA in mouse liver subcellular
fractions seemed to correlate well with that of acyl-CoA formation of
palmitic acid (a substrate for long-chain acyl-CoA synthetase) (Fig.
7A) and the activity of cytochrome c reductase, a marker enzyme for
microsomes, but not with the rate of acyl-CoA formation of octanoic
acid (a substrate for medium-chain acyl-CoA synthetase) (Fig. 7B)
and the activities of marker enzymes for other subcellular fractions.
These observations clearly indicated that acyl-CoA formation of SVA
is catalyzed preferentially by microsomal enzyme(s).
Discussion
The present studies provide direct experimental evidence for the
formation of acyl-CoA thioester of SVA in vitro in mouse liver
preparations. Using the HPLC methods described above, acyl-CoA
thioester intermediates of SVA were completely resolved from other
peaks present following incubations with mouse liver preparations.
Under such HPLC conditions optimized for acyl-CoA thioesters, we
were able to isolate and fully characterize these acyl-CoA thioester
intermediates by LC-MS/MS and NMR analysis. The optimized
HPLC method also provides a possible explanation for the reason why
the CoA thioester conjugates of SVA were not observed in our
previous studies with mouse liver preparations (Prueksaritanont et al.,
2001). Preliminary studies showed that SVA-CoA and P1-CoA were
sensitive to pH of mobile phase and did not chromatograph well under
acidic conditions, such as 0.1% formic acid, the condition used in our
previous studies (Prueksaritanont et al., 2001). Similar observations
were also made for other xenobiotic acyl-CoA thioesters, such as
2-phenylpropionyl-S-acyl CoA (Li et al., 2002), 2,4-dichlorophenoxy-
acetyl-S-acyl CoA (Li et al., 2003), and naproxen-S-acyl CoA (Olsen
et al., 2002). Recently, Sidenius el al. (2004) reported several LC
chromatographic methods developed for analysis of acyl-CoA thio-
esters of eight structurally diverse carboxylic acids, including ibupro-
fen, clofibric acid, indomethacin, fenbufen, tolmetin, salicylic acid,
2-phenoxypropionic, and 4-chloro-2-methyl-phenoxyacetic acid. No-
tably, the pH of mobile phases used for the eight acyl-CoA thioesters
were all between 6 and 7.
As pointed out by Halpin et al. (1993), -oxidation of fatty acids
requires that hydroxylated intermediates be in the L-configuration,
whereas in the case of statins, both the 4- and 6-hydroxyl groups on
the side chain possess the D-configuration required for pharmacolog-
ical activity (Fig. 1). An epimerization to L-configuration has been
proposed to be an essential step for D--hydroxyacyl CoA thioester to
enter the -oxidation cycles (Halpin et al., 1993) (Fig. 1). Recent in
vitro studies with SVA provided evidence supporting that epimeriza-
tion of D--hydroxy statin acyl CoA proceeded via the dehydration at
the  and  carbons with respect to the carboxy carbon to give a
trans-enoyl-CoA, followed by stereospecific hydration of the unsat-
urated acyl-CoA to give rise to the L--hydroxy isomer (Prueksarit-
anont et al., 2001) (Fig. 1). However, the corresponding dehydration
(P1) and stereospecific rehydration (P2, L,D-dihydroxy isomer of
SVA) intermediates were detected only in their free acid forms
(Prueksaritanont et al., 2001). Under the current HPLC conditions, we
were able to detect the acyl-CoA thioester of the dehydration product,
namely P1-CoA, in addition to its free acid form P1. However, the
peak corresponding to acyl-CoA thioester of P2 (P2-S-acyl coenzyme
A, P2-CoA) was not observed in the present study. The reason for this
remains unclear. It is possible that formation of P2-CoA is low under
current incubation conditions and could not be detected by HPLC
analysis.
In addition to mediating the -oxidation of statins, the bioactivated
acyl-CoA thioesters have been hypothesized to be a key intermediate
for the formation of statin lactones (Duggan and Vickers, 1990). The
hypothesis has been substantiated by recent findings of CoASH-
dependent formation of simvastatin lactone in vitro in mouse liver
preparations (Prueksaritanont et al., 2001). Similar observations on
simvastatin formation were also made in the present study. In addition
to simvastatin, we found a new lactone metabolite of SVA, M1
(L--hydroxy isomer of simvastatin), possibly formed by lactonization
of P2-CoA, and its structure has been identified definitively (Fig. 1).
Our finding that the extent of formation of simvastatin and M1
increased when the corresponding acyl-CoA formation (SVA-CoA
and P1-CoA) increased (Fig. 6) provides additional evidence that the
lactonization of the statin hydroxy acids (SVA and P2) could be
mediated by acyl-CoA thioesters via an intramolecular acylation.
Considering the well documented interconversion between SVA and
simvastatin, it is anticipated that interconversion between P2 and M1
might also exist (Fig. 1). Both P2 and M1 are pharmacologically
inactive, and the relevance of the in vitro formation of M1 to in vivo
situation is currently unclear. The formation of M1 has not been
reported in vivo following administration of SVA or simvastatin to
humans and animals. This might be partly due to the chromatographic
conditions used in the previous in vivo studies, which were not
optimized for the detection of M1. It is also possible that formation of
M1 is relatively low in vivo if the subsequent -oxidation of P2-CoA
is more favorable than the corresponding lactonization process
(Fig. 1).
In agreement with previous data (Krisans et al., 1980; Knights and
Drogemuller, 2000), our study showed that long-chain acyl-CoA
synthetase (measured by PA-CoA synthetase) was primarily localized
in microsomes and to a lesser extent in mitochondria (MT-H and
MT-L) (Fig. 7A), whereas medium-chain acyl-CoA synthetase (mea-
sured by OA-CoA synthetase) was mainly located in mitochondria
(MT-H and MT-L) (Fig. 7B), which further confirmed the purity of
subcellular fractions obtained. Studies with these subcellular fractions
revealed that CoASH-dependent SVA metabolism occurred preferen-
tially in microsomes and to a lesser extent in mitochondria (MT-H and
MT-L) with no activity observed in cytosol (Fig. 7C). This distribu-
tion of activity correlated well with that of long-chain acyl-CoA
synthetase but not with that of medium-chain acyl-CoA synthetase,
suggesting the potential involvement of long-chain acyl-CoA syn-
thetase in the acyl-CoA formation of SVA. This observation was
further supported by our preliminary studies that showed that CoASH-
dependent metabolism of SVA was effectively inhibited by palmitic
acid and triacsin C (10 M), a potent and selective inhibitor for
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long-chain acyl-CoA synthetase (Vessey et al., 2004). In contrast, the
enzymes potentially involved in the hydrolysis of SVA-CoA and
P1-CoA were still poorly understood. It seemed that other subcellular
fractions (e.g., mitochondria and cytosol), in addition to microsomes,
might contribute significantly to the hydrolysis of P1-CoA, based on
the fact that P1 levels were not significantly increased when the
corresponding P1-CoA was increased by 5- to 7-fold in liver micro-
somes compared with liver S0.6 (Fig. 6). This observation is consis-
tent with the previous reports on the wide subcellular distribution of
acyl-CoA hydrolases (Urrea and Bronfman, 1996; Garras et al., 1997).
It is noteworthy that formation of statin acyl-CoA thioesters is not
expected to be unique for SVA. Other statin hydroxy acids, including
cerivastatin and atorvastatin, which all share the common D,D-dihy-
droxy acid side chain, undergo -oxidation and, therefore, are antic-
ipated to be able to form the acyl-CoA thioesters. In fact, our prelim-
inary studies with cerivastatin and atorvastatin showed that acyl-CoA
thioesters of these statin acids were readily detectable in vitro in
mouse liver preparations. Additionally, consistent with the in vivo
observations on the -oxidation of statins (Reinoso et al., 2002),
species differences in the formation of acyl-CoA thioesters were also
observed in our preliminary studies, which showed that acyl-CoA
thioesters of statin hydroxy acids, including SVA, cerivastatin, and
atorvastatin, were detectable only with liver preparations from mice
and rats but not from dogs and humans. However, such marked
species differences were not observed in vivo for the formation of
statin lactones. Significant lactone formation was reported to occur in
vivo following administration of SVA or cerivastatin to dogs and of
cerivastatin and atorvastatin to humans (Vickers et al., 1990; Boberg
et al., 1998; Kantola et al., 1998, 1999) in addition to rodents,
suggesting that more than one metabolic pathway might contribute to
the formation of statin lactones. In fact, a recent study showed that
acyl glucuronides also mediated the lactone formation (Prueksarit-
anont et al., 2002a). Quantitatively, there seem to be differences in the
relative contribution of these two metabolic pathways to the lactone
formation of different statins in different species. In rodents, acyl-
CoA pathway is most likely to contribute significantly to the forma-
tion of statin lactones based on the fact that -oxidation of statins has
been shown to be a major pathway in these species (Reinoso et al.,
2002). Conversely, in dogs, acyl glucuronidation seems to play a more
important role in the lactonization of statins than acyl-CoA formation;
statins have been shown to undergo significant acyl glucuronidation
and minimal -oxidation in vivo in dogs (Vickers et al., 1990; Boberg
et al., 1998; Black et al., 1999; Prueksaritanont et al., 2002a). Unfor-
tunately, such a conclusion could not be readily drawn in humans due
to limited in vivo data. Nevertheless, based on the findings on acyl
glucuronidation in human liver preparations in vitro and in animals in
vitro and in vivo (Prueksaritanont et al., 2002a), it is anticipated that
acyl glucuronidation plays a role in the lactonization of statin acids in
vivo in humans.
In conclusion, this was the first study to demonstrate the formation
of acyl-CoA thioesters of SVA and subsequent metabolites in vitro in
mouse liver preparations. Our results support the hypothesis that
-oxidation occurs as a consequence of acyl-CoA thioester formation,
possibly by microsomal long-chain acyl-CoA synthetase(s) and sub-
sequent epimerization. Additionally, the present studies also provide
evidence that formation of these thioesters contributes, at least in part,
to interconversion between SVA and its diastereomer and between
these hydroxy acids and their corresponding lactones. Similar obser-
vations are also anticipated with other hydroxy acid forms of statins
(and their diastereomers) and the corresponding lactones.
Acknowledgments. We thank Scott Fauty and Todd Killino for
mouse liver preparations and Dr. Don Slaughter for critical review of
the manuscript.
References
Baudhuin P, Beaufay H, Rahman LO, Selliner OZ, Wattiaux R, Jacques P, and de Duve C (1964)
Tissue fractionation studies. Biochem J 92:179–184.
Beaufay H, Amar-Cortesec A, Feytmans E, Thines-Sempoux D, Wibo M, Mobbi MN, and
Berhet T (1974) Analytical study of microsomes and isolated subcellular membranes from rat
liver. 1. Biochemical methods. J Cell Biol 61:188–200.
Bjorge SM and Baillie TA (1991) Studies of the -oxidation of valproic acid in rat liver
mitochondrial preparations. Drug Metab Dispos 19:823–829.
Black AE, Hayes RN, Roth BD, Woo P, and Woolf TF (1999) Metabolism and excretion of
atorvastatin in rats and dogs. Drug Metab Dispos 27:916–923.
Boberg M, Angebauer R, Kanhai WK, Karl W, Kern A, Radtke M, and Steinke W (1998)
Biotransformation of cerivastatin in mice, rats and dogs in vivo. Drug Metab Dispos 26:640–
652.
Duggan DE and Vickers S (1990) Physiological disposition of HMG-CoA-reductase inhibitors.
Drug Metab Rev 22:333–362.
Garras A, Elholm M, Sleboda J, Froyland L, Osmundsen H, and Berge RK (1997) On the effects
of thia fatty acid analogues on hydrolases involved in the degradation of metabolisable and
non-metabolisable acyl-CoA esters. Xenobiotica 27:781–799.
Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, and Duggan DE (1993)
Biotransformation of lovastatin V. Species differences in in vivo metabolite profiles of mouse,
rat, dog and human. Drug Metab Dispos 21:1003–1011.
Hatanaka T (2000) Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetics
events. Clin Pharmacokinet 39:397–412.
Igel M, Sudhop T, and von Bergmann K (2001) Metabolism and drug interaction of 3-hydroxy-
3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357–
364.
Kantola T, Kivisto KT, and Neuvonen PJ (1998) Effect of itraconazole on cerivastatin pharma-
cokinetics. Eur J Clin Pharmacol 54:851–855.
Kantola T, Kivisto KT, and Neuvonen PJ (1999) Effect of itraconazole on the pharmacokinetics
of atorvastatin. Clin Pharmacokinet Ther 64:58–65.
Knights KM and Drogemuller CJ (2000) Xenobiotic-CoA ligases: kinetic and molecular char-
acterization. Curr Drug Metab 1:49–66.
Krisans SK, Mortensen RM, and Lazarow PB (1980) Acyl-CoA synthetase in rat liver peroxi-
somes. J Biol Chem 255:9599–9607.
Li C, Benet LZ, and Grillo MP (2002) Enantioselective covalent binding of 2-phenylpropionic
acid to protein in vitro in rat hepatocytes. Chem Res Toxicol 15:1480–1487.
Li C, Grillo MP, and Benet LZ (2003) In vitro studies on the chemical reactivity of 2,4-
dichlorophenoxyacetyl-S-acyl-CoA thioester. Toxicol Appl Pharmacol 187:101–109.
Martin PD, Dane AL, Schneck DW, and Warwick MJ (2000) Disposition of new HMG-CoA
reductase inhibitor ZD4522 following dosing in healthy subjects. J Clin Pharmacol 40:1056.
Olsen J, Bjornsdottir I, Tjornelund J, and Honore Hansen S (2002) Chemical reactivity of the
naproxen acyl glucuronide and the naproxen coenzyme A thioester towards bionucleophiles.
J Pharma Biomed Anal 29:7–15.
Prueksaritanont T, Ma B, Fang X, Subramanian R, Yu J, and Lin JH (2001) -Oxidation of
simvastatin in mouse liver preparations. Drug Metab Dispos 29:1251–1255.
Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, and Baillie TA
(1999) Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in
vitro investigation with human liver preparations. Br J Clin Pharmacol 47:291–298.
Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA
(2002a) Glucuronidation of statins in animals and humans: A novel mechanism of statin
lactonization. Drug Metab Dispos 30:505–512.
Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, and Lin JH (2002b) Effects of fibrates
on metabolism of statins in human hepatocytes. Drug Metab Dispos 30:1280–1287.
Reinoso RF, Navarro AS, Garcia MJ, and Prous JR (2002) Preclinical pharmacokinetics of
statins. Methods Find Exp Clin Pharmacol 24:593–613.
Sellinger OZ, Beaufay H, Jacques P, Doyer A, and de Duve C (1960) Tissue fractionation
studies. Biochem J 74:450–456.
Sidenius U, Skonberg C, Olsen J, and Hansen SH (2004) In vitro reactivity of carboxylic
acid-CoA thioesters with glutathione. Chem Res Toxicol 17:75–81.
Urrea R and Bronfman M (1996) Species differences in the intracellular distribution of cipro-
fibryl-CoA hydrolase. Implications for peroxisome proliferation. FEBS Lett 389:219–223.
Vessey DA, Kelley M, and Warren RS (2004) Characterization of triacsin C inhibition of short-,
medium- and long-chain fatty acid:CoA ligases of human liver. J Biochem Mol Toxicol
18:100–106.
Vickers S, Duncan CA, Chen I-W, Rosegay A, and Duggan DE (1990) Metabolic disposition
studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18:138–145.
Volkl A and Fahimi HD (1985) Isolation and characterization of peroxisomes from the liver of
normal untreated rats. Eur J Biochem 149:257–265.
Address correspondence to: Dr. Chunze Li, Department of Drug Metabolism,
Merck Research Laboratories, WP 75-100, P. O. Box 4, West Point, PA 19486.
E-mail: chunze_li@merck.com.
110 LI ET AL.
